John Turman Fleming Sells 2,450 Shares of USANA Health Sciences (NYSE:USNA) Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director John Turman Fleming sold 2,450 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $17.93, for a total transaction of $43,928.50. Following the transaction, the director directly owned 4,230 shares in the company, valued at approximately $75,843.90. This represents a 36.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

USANA Health Sciences Trading Down 0.2%

NYSE USNA traded down $0.04 during trading on Monday, reaching $18.26. The company’s stock had a trading volume of 132,203 shares, compared to its average volume of 125,823. The firm has a 50 day moving average price of $18.31 and a 200 day moving average price of $19.47. USANA Health Sciences, Inc. has a 12 month low of $16.60 and a 12 month high of $38.32. The firm has a market capitalization of $337.12 million, a price-to-earnings ratio of 38.86, a price-to-earnings-growth ratio of 0.72 and a beta of 0.77.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, May 5th. The company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.44 by $0.17. USANA Health Sciences had a net margin of 0.96% and a return on equity of 6.21%. The company had revenue of $250.22 million for the quarter, compared to analysts’ expectations of $240.99 million. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. On average, equities analysts forecast that USANA Health Sciences, Inc. will post 2.12 EPS for the current fiscal year.

Institutional Trading of USANA Health Sciences

Large investors have recently made changes to their positions in the company. National Bank of Canada FI increased its position in USANA Health Sciences by 166.6% in the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after buying an additional 1,201 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in USANA Health Sciences by 382.5% in the second quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock worth $73,000 after acquiring an additional 1,901 shares in the last quarter. State of Wyoming acquired a new stake in USANA Health Sciences in the first quarter valued at approximately $57,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of USANA Health Sciences by 52.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock valued at $106,000 after acquiring an additional 1,327 shares in the last quarter. Finally, Parallel Advisors LLC raised its position in shares of USANA Health Sciences by 1,354.3% during the fourth quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock worth $76,000 after purchasing an additional 3,589 shares during the period. 54.25% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a report on Friday, March 27th. Zacks Research lowered shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 22nd. Finally, Wall Street Zen cut USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Reduce”.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.